Standard Biotools Inc.: Form 10-Q for the period ended Jun 30, 2015
Filed with the SEC on Aug 10, 2015 and accepted by EDGAR at Aug 7, 2015, 21:40 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-04-01 to 2015-06-30 | $28.6m | us-gaap:Revenues |
| Revenue | 6 months2015-01-01 to 2015-06-30 | $55.3m | us-gaap:Revenues |
| Cost of revenue | 3 months2015-04-01 to 2015-06-30 | $12.0m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2015-01-01 to 2015-06-30 | $22.6m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2015-04-01 to 2015-06-30 | $10.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2015-01-01 to 2015-06-30 | $20.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2015-04-01 to 2015-06-30 | $21.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2015-01-01 to 2015-06-30 | $41.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2015-04-01 to 2015-06-30 | −$14.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2015-01-01 to 2015-06-30 | −$28.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-04-01 to 2015-06-30 | $1.5m | us-gaap:InterestExpense |
| Interest expense | 6 months2015-01-01 to 2015-06-30 | $2.9m | us-gaap:InterestExpense |
| Income tax | 3 months2015-04-01 to 2015-06-30 | −$266.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2015-01-01 to 2015-06-30 | −$909.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-04-01 to 2015-06-30 | −$15.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2015-01-01 to 2015-06-30 | −$31.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-04-01 to 2015-06-30 | −$0.53 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2015-01-01 to 2015-06-30 | −$1.09 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2015-01-01 to 2015-06-30 | −$17.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2015-01-01 to 2015-06-30 | $2.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-06-30 | $23.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-06-30 | $143.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-06-30 | $389.1m | us-gaap:Assets |
| Current liabilities | At period end2015-06-30 | $28.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-06-30 | $255.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-06-30 | $133.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001162194-15-000139. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.